Target intelligence / Profile preview

PCDH9 antisense RNA 3 (PCDH9-AS3)

Target
PCDH9-AS3
Molecular classification
Long non-coding RNA (lncRNA), Non-protein coding RNA
01

Overview

PCDH9 antisense RNA 3 (PCDH9-AS3) is a long non-coding RNA transcribed in the antisense orientation from the PCDH9 gene locus at chromosome 13q21.32. It does not encode a protein. Its sequence and expression are cataloged in major gene databases, but there are currently no established molecular functions or biological pathways clearly attributed to this transcript. The lncRNA is likely "non-exonic," meaning it overlaps intronic regions of the PCDH9 locus. There is currently no evidence for direct involvement in disease or for being a therapeutic target, though regulatory lncRNAs at similar loci sometimes participate in modulating neighboring gene expression—such as protocadherin genes thought to play roles in neural adhesion and signaling. There are no interacting drugs, biomarkers, or specific safety concerns relevant to clinical practice, and PCDH9-AS3 is not a target for current therapies. Notes: - The target is sometimes confused with nearby or similar lncRNAs such as PCDH9-AS2 or PCDH9-AS4. - Existing literature and genomic databases confirm identity but lack deeper functional annotation. If more molecular or pathophysiological detail emerges in future studies, re-evaluation may reveal regulatory or disease associations.

Other names
PCDH9 antisense RNA 3 (non-protein coding)PCDH9-AS3PCDH9 antisense RNA 4PCDH9-AS4
02

Mechanism of action

None (no drugs are known to target this lncRNA; mechanisms of action would likely involve RNA-based therapeutic strategies if investigated)

03

Biological functions

Other (Potentially involved in the regulation of PCDH9 expression or in local chromatin structure; explicit roles have not been robustly defined in published literature)
04

Disease associations

Other (No clear evidence for involvement in major disease categories; possible associations could exist with neurological or developmental disorders via regulatory connection to PCDH9, but no direct clinical or GWAS links are present)

Beyond the preview

Go deeper on PCDH9 antisense RNA 3 (PCDH9-AS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCDH9 antisense RNA 3 (PCDH9-AS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call